Audited Financial Results for the 4TH Quarter and Financial Year ended 31.03.2026

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹510.70

prior close

₹529.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.6%-2.9% vs market

Healthcare Research Analytics & Technology peers, median of 5sector+2.6%-3.9% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+7.5

10m

+4.8

15m

+4.0

30m

+2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+1.6-2.9+2.6-3.9

Next day

+0.5+1.5-1.0+2.4-1.9

-3.7+0.0-3.7+2.2-5.8

-8.3-3.0-5.3-0.9-7.4

-8.5-2.4-6.1-2.1-6.4

-10.3-2.1-8.2-3.1-7.2

-13.1-3.8-9.3+3.6-16.7

15d

-7.4-0.0-7.3-1.8-5.6

+2.4-1.0+3.4-0.8+3.2

+8.2+6.5+1.7-6.1+14.3

+27.7+10.2+17.6+1.5+26.3

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vimta Labs Limited reported audited financial results for FY2025-26 with total income of Rs 4,162.79 million, up 19.6% from Rs 3,482.22 million in the previous year. Revenue from operations grew 18.4% to Rs 4,072.90 million. Profit after tax from continuing operations increased to Rs 775.12 million from Rs 667.55 million, representing 16.1% growth. The company also completed a bonus share issue in 1:1 ratio during the year. Statutory auditors issued an unmodified (clean) opinion. The board recommended a dividend of Rs 2 per share and approved setting up a wholly owned subsidiary in the USA. The diagnostic business sold to Thyrocare contributed Rs 5.87 million to total profit after tax.

Likely market impact

Strong revenue and profit growth with clean audit opinion signals healthy operational performance. The bonus issue and dividend recommendation are positive for shareholders. Expansion plans via USA subsidiary may require monitoring for capital deployment impact.